Exciting News! FDA Clears Aruna Bio's IND for AB126 – A Major Milestone in Advancing Medical Innovation!! We are thrilled to announce a groundbreaking achievement for Aruna Bio as the FDA grants clearance for the Investigational New Drug (IND) application for AB126! This milestone represents a testament to our unwavering commitment to advancing medical innovation and bringing transformative solutions to patients in need. AB126, a first-in-class neural exosome, holds great promise in treating both acute and chronic CNS indications. Our dedicated team has worked tirelessly to reach this stage, and we are excited about the potential impact that AB126 can have on acute ischemic stroke and chronic neurodegenerative conditions. Thank you to everyone who has been part of this journey. Stay tuned for more updates as we continue to innovate! Learn More: https://lnkd.in/eMWcA7Dg #healthcareadvancements #biotechinnovation #stroke #stroketreatment #cns
About us
Aruna Bio is harnessing the natural abilities of neural exosomes to cross the blood brain barrier and enhance the body’s anti-inflammatory, self-repair and protective mechanisms to treat a range of neurodegenerative disorders. We are leveraging our proprietary exosomes and manufacturing platform to create synergistic therapies by enhancing our exosomes with small molecules, RNA, oligonucleotides and antibodies.
- Website
-
http://www.arunabio.com
External link for Aruna Bio, Inc.
- Industry
- Research Services
- Company size
- 11-50 employees
- Headquarters
- Athens, GA
- Type
- Educational
- Founded
- 2003
- Specialties
- Stem cells, Neural stem cells, Drug toxicity assay, high throughput screening services, stroke, exosome, CNS, neurodegenerative disorders, and drug development
Locations
-
Primary
Get directions
425 River Road
Athens, GA 30602, US
Employees at Aruna Bio, Inc.
-
Skip Irving
Chairman, The Michael J. Fox Foundation for Parkinson's Research
-
Tracey Worthington Stice
Chief Operating Officer
-
Steven Stice
D. W. Brooks Distinguished Professor; GRA Scholar; Director of Regenerative Bioscience Center at University of Georgia
-
Stephen From
Chief Executive Officer at Aruna Bio, Inc.
Updates
-
Attending BIO 2024? Click below to send Aruna Bio a meeting request in the BIO partnering system! #BIO2024 https://lnkd.in/dA5REsef
BIO One-on-One Partnering
login.partnering.bio.org
-
Our CEO Stephen From will be attending BIO International 2024 in San Diego, CA. The CNS space is a very exciting and active therapy area, and we would love to connect with those who share our passion for exosomes and exosome-based therapeutics. Any parties interested in connecting should reach out via the BIO Partnering platform, or send an email to [email protected]. #BIO2024
-
🧠Extracellular Vesicles hold immense potential as therapeutic agents, offering targeted delivery and unique modes of intercellular communication. 🔖 Read more about a recent publication by Dr. Steven Stice from The University of Georgia on Advancement of Extracellular Vesicle (EV) therapeutics into clinical trials for Central Nervous System (CNS) disorders at https://lnkd.in/dXUKmd6x. #Neuroscience #ExtracellularVesicles #Therapeutics #ClinicalTrials #CNSDisorders #Innovation #BiomedicalResearch
-
🔬 Aruna Bio establishes Stroke Advisory Board to support AB126 development! We are thrilled to announce the establishment of our Stroke Advisory Board, a crucial step forward in shaping our first clinical trial. 👥 Connect with Our Advisors: Sean Savitz Lawrence Wechsler David Y. Huang, MD/PhD, FAHA, FAAN Thanh Nguyen Charles Green Johannes Boltze, M.D., Ph.D. 📚 Learn More: [https://lnkd.in/efBUYZwQ] Join us in this exciting journey as we advance biotechnological solutions for better stroke outcomes! 🌍 #BiotechInnovation #StrokeResearch #ClinicalTrial #AdvisoryBoard #ArunaBio
-
Our CEO Stephen From participated in a one-on-one interview with NeurologyLive to discuss the recent FDA clearance of Aruna Bio's IND for AB126 to treat stroke patients. View the article here: https://lnkd.in/epv_3WdD
NeuroVoices: Stephen From, on AB126 and Exosomes in Treating Stroke
neurologylive.com
-
Aruna Bio, Inc. reposted this
The FDA has cleared Aruna Bio, Inc.’s investigational new drug application for the company’s lead candidate AB126, an unmodified neural-derived exosome, according to a new announcement. Read: https://lnkd.in/exnHJFBp
FDA Clears Aruna Bio’s Exosome AB126 for Clinical Trials in Neurological Indication
neurologylive.com
-
We are thrilled to share that our CEO Stephen From will be attending the highly anticipated JP Morgan Healthcare Conference in 2024! As a premier event in the healthcare industry, the JP Morgan Conference serves as a nexus for key leaders, innovators, and visionaries in healthcare. It’s an unparalleled platform to discuss industry trends, groundbreaking innovations, and the future of healthcare. Any parties interested in connecting should reach out via the BIO Partnering platform, or send an email to [email protected]. #JPMorganHealthcare #HealthcareInnovation #LeadershipInHealthcare
Health Care Conference
jpmorgan.com
-
Recently, Aruna Bio reported new preclinical data demonstrating the ability of its unmodified neural-derived exosome, AB126, to prolong survival and reduce inflammation in a superoxide dismutase 1 (SOD1) amyotrophic lateral sclerosis (ALS) mouse model. Read the press release here: https://lnkd.in/e9HNi8w7
Aruna Bio Announces Preclinical Results from Pilot Study Evaluating AB126 for the Treatment of Amyotrophic Lateral Sclerosis
globenewswire.com